Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Yatharth Hospital & Trauma Care Services Ltd. Share Price
Day's Range
Day's Range
Low
₹807.50
High
₹833.55
Price Summary
| Previous Close | ₹821.85 |
|---|---|
| Day's Range | ₹807.50 - ₹833.55 |
| Open | ₹820.00 |
| 52 Week Range | ₹451.50 - ₹843.70 |
| Volume | 4,12,655 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 3,399.44 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 47.35 |
| TTM EPS (₹) | 17.37 |
| P/E Ratio | 31.35 |
| Book Value(₹) | 4.58 |
| PAT Margin (%) | 14.83 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 14.35 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1104.11 | 4197.91 |
| Expenses | N/A | N/A |
| PBT | 296.22 | 1131.14 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 222.53 | 839.94 |
About Yatharth Hospital & Trauma Care Services Ltd.
| Founded | 2008 |
|---|---|
| Managing Director | Kapil Kumar |
| NSE Symbol | YATHARTH |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,37,662.69 | 1,824.10 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,75,692.42 | 6,618.20 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,43,908.69 | 4,252.05 | 3,101.60 - 3,101.60 |
| Apollo Hospitals Enterprise Ltd. | 1,11,261.29 | 7,727.50 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,07,826.86 | 1,334.85 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,07,499.64 | 1,287.95 | 1,129.40 - 1,129.40 |
| Lupin Ltd. | 1,07,489.16 | 2,350.00 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 98,438.74 | 1,011.45 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 93,323.97 | 2,266.80 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 90,727.09 | 901.65 | 835.50 - 835.50 |
No Records Found
Latest News
Albert David informs about board meeting
In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Albert David has informed that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, the May 12, 2026, to: 1. Consider, approve and take on record the Audited Financial Results of the Company for the Fourth Quarter and Financial Year ended on March 31, 2026. 2. Consider recommendation of Final Dividend, if any, for the Financial Year ended on March 31, 2026. The trading window for dealing in equity shares of the Company is already closed from April 1, 2026, and shall open 48 hours post declaration of the above results. The above notice is also being made available on the website of the Company at www.albertdavidindia.com.
The above information is a part of company’s filings submitted to BSE.
Rainbow Children's Medicare informs about updates
Wockhardt informs about press release
Venus Remedies informs about updates
GKB Ophthalmics informs about board meeting
Pursuant to Regulation 29 read with Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, GKB Ophthalmics has informed that a Meeting of the Board of Directors of the Company will be held on Wednesday, May 27, 2026 at the Registered Office of the Company, to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026. The Notice can be accessed at the Company's website at www.gkb.net. Further, with reference to the above meeting of the Board of Directors that the Trading Window for dealing with equity shares of the Company, by designated persons, under the SEBI (Prohibition of Insider Trading) Regulations, 2015, had been closed from April 01, 2026, will now re-open after the completion of 48 hours from the date of submission of financial results to the Stock Exchange. This communication has been sent to all the Directors and all the designated employees of the Company.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Yatharth Hospital & Trauma Care Services Ltd. is ₹821.85 as of 2026-05-04.
The market capitalisation of Yatharth Hospital & Trauma Care Services Ltd. is ₹7,924.66 as of 2026-05-04.
The 1-year return of Yatharth Hospital & Trauma Care Services Ltd. is 0.00% as of 2026-05-04.
The P/E ratio of Yatharth Hospital & Trauma Care Services Ltd. is 31.35 as of 2026-05-05.
The 52-week high and low of Yatharth Hospital & Trauma Care Services Ltd. are ₹843.70 and ₹451.50, respectively, as of 2026-05-04.
People Also Ask
Yatharth Hospital & Trauma Care Services Ltd. collaborates with pharmaceutical companies and other healthcare entities through clinical practices, procurement of medical equipment, and integration of healthcare technologies. Its hospitals may also serve as clinical settings for treatment protocols and the use of advanced medical devices, while partnering with suppliers to maintain modern healthcare infrastructure.
Yatharth Hospital & Trauma Care Services Ltd. operates multi-specialty hospitals, primarily located in the National Capital Region (NCR). Its facilities provide a range of healthcare services, including trauma care, cardiology, orthopedics, and critical care, supported by intensive care units and related medical infrastructure.
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
